Risk Stratification and New Early Prevention and Treatment Strategies for Patients With Cardiomyopathy (STRENGTH)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorFirst Affiliated Hospital Xi'an Jiaotong University

About this trial

This study will include patients with different types of cardiomyopathy from multiple centers were prospectively enrolled in a retrospective study to establish a natural population cohort of cardiomyopathy patients. By collecting clinical data and biological samples from surgical patients, we will construct a prognostic system for cardiomyopathy, optimize risk stratification, explore new strategies for the early prevention and treatment of cardiomyopathy, and improve the efficiency of clinical cardiomyopathy patients' diagnosis and treatment.

Eligibility criteria

Qualifiers

Age >18 years old.

The diagnosis of cardiomyopathy was confirmed by cardiac ultrasound, electrocardiogram, magnetic resonance angiography, pathological examination and gene sequencing.

Patients or their families agreed to participate in the study and authorized informed consent.

Disqualifiers

Incomplete clinical data.

Do not agree to the inclusion or refuse to authorize the informed consent.

Trial design

Treatments tested in this trial

  • Diagnosis of HCM
  • Diagnosis of DCM
  • Diagnosis of ARVC
  • Diagnosis of NDLVC
  • Diagnosis of RCM
  • Diagnosis of LVNC

Treatment groups

500 Participants
are divided into 6 treatment groups

6

Treatment groups

See each treatment group below.